Acasunlimab（Cat No.:I042186）is an investigational monoclonal antibody that targets TIGIT (T-cell immunoreceptor with Ig and ITIM domains), an immune checkpoint receptor found on immune cells. TIGIT plays a role in suppressing immune responses, particularly within the tumor microenvironment, allowing cancers to evade immune detection. By inhibiting TIGIT, acasunlimab aims to enhance T-cell activity and restore the immune system’s ability to recognize and eliminate cancer cells. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors, with the goal of improving immune responses and patient outcomes.
